Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study

MT Newswires Live09-18

Tivic Health Systems (TIVC) said Wednesday it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation technology.

The clinical research collaboration with Feinstein is designed to advance the development of its ncVNS technology by refining and optimizing stimulation parameters, the company said.

Insights from the study will guide the selection of clinical populations and help shape the design of future clinical trials, with key goals of the current study including optimizing treatment strategies and accelerating product development, the firm said.

Tivic also said it partnered with Fletcher Spaght, a healthcare growth strategy firm, to explore potential clinical applications of its ncVNS system that address high unmet medical needs.

"We are taking an integrated approach to clinical, product development and go-to-market planning for our medical-grade non-invasive VNS program," said Chief Executive Jennifer Ernst. "We believe this approach creates the best opportunities to generate significant new revenue based on this work."

Price: 0.28, Change: +0.01, Percent Change: +2.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468587766?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-18 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468587766","market":"sg","top_or_hot":-1,"title":"Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study","media":"MT Newswires Live","content":"<html><body><p> Tivic Health Systems (TIVC) said Wednesday it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation technology.</p><p>The clinical research collaboration with Feinstein is designed to advance the development of its ncVNS technology by refining and optimizing stimulation parameters, the company said.</p><p>Insights from the study will guide the selection of clinical populations and help shape the design of future clinical trials, with key goals of the current study including optimizing treatment strategies and accelerating product development, the firm said.</p><p>Tivic also said it partnered with Fletcher Spaght, a healthcare growth strategy firm, to explore potential clinical applications of its ncVNS system that address high unmet medical needs.</p><p>\"We are taking an integrated approach to clinical, product development and go-to-market planning for our medical-grade non-invasive VNS program,\" said Chief Executive Jennifer Ernst. \"We believe this approach creates the best opportunities to generate significant new revenue based on this work.\"</p><p>Price: 0.28, Change: +0.01, Percent Change: +2.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Gets Institutional Review Board's Approval for ncVNS Optimization Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-18 22:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tivic Health Systems (TIVC) said Wednesday it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIVC","symbol_name":"Tivic Health Systems, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468587766","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468587766","pubTimestamp":1726670011,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tivic Health Systems  said Wednesday it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation technology.The clinical research collaboration with Feinstein is designed to advance the development of its ncVNS technology by refining and optimizing stimulation parameters, the company said.Insights from the study will guide the selection of clinical populations and help shape the design of future clinical trials, with key goals of the current study including optimizing treatment strategies and accelerating product development, the firm said.Tivic also said it partnered with Fletcher Spaght, a healthcare growth strategy firm, to explore potential clinical applications of its ncVNS system that address high unmet medical needs.\"We are taking an integrated approach to clinical, product development and go-to-market planning for our medical-grade non-invasive VNS program,\" said Chie","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIVC":"Tivic Health Systems, Inc.","BK4082":"医疗保健设备"},"translate_title":"Tivic Health获得机构审查委员会批准ncVNS优化研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":0.9},"content_text":"Tivic Health Systems (TIVC) said Wednesday it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation technology.The clinical research collaboration with Feinstein is designed to advance the development of its ncVNS technology by refining and optimizing stimulation parameters, the company said.Insights from the study will guide the selection of clinical populations and help shape the design of future clinical trials, with key goals of the current study including optimizing treatment strategies and accelerating product development, the firm said.Tivic also said it partnered with Fletcher Spaght, a healthcare growth strategy firm, to explore potential clinical applications of its ncVNS system that address high unmet medical needs.\"We are taking an integrated approach to clinical, product development and go-to-market planning for our medical-grade non-invasive VNS program,\" said Chief Executive Jennifer Ernst. \"We believe this approach creates the best opportunities to generate significant new revenue based on this work.\"Price: 0.28, Change: +0.01, Percent Change: +2.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468587766"}